Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 30;20(19):4867. doi: 10.3390/ijms20194867

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Figure 8. Drug toxicity experiments. (A) Schematic representation of cisplatin toxicity experiments in met-IPSC kidney embryoid bodies. (B–C) Representative whole-mount immunostaining for LTL, KIM-1 and DAPI in control iPSC-derived kidney embryoid bodies treated with cisplatin (500 µg/mL) (right panels). (D–E) Representative whole-mount immunostaining for LTL, KIM-1 and DAPI in met-IPSC-derived kidney embryoid bodies treated with cisplatin (500 µg/mL) (right panels). (F) Schematic of drug Sunitinib toxicity test process of met-IPSC-derived kidney embryoid bodies. (G) Photograph of met-IPSC-derived kidney embryoid bodies in 96 well plate. (H) Representative whole-mount immunostaining for PODXL, KIM-1 and DAPI in met-IPSC-derived kidney embryoid bodies treated with Sunitinib (20 µg/mL). (I) Representative whole-mount immunostaining for PODXL, KIM-1 and DAPI in met-IPSC-derived kidney embryoid bodies treated with Sunitinib (500 µg/mL), Scale bar: 100 μm.